0.476  -0.001 (-0.21%)		04-26 13:29
Open: 0.48 High: 0.48 Volume: 1,271,584		Pre. Close: 0.477 Low: 0.459 Market Cap: 566(M)

Short term
Mid term
Targets	6-month :	9.91	1-year :	11.58
Resists	First :	8.48	Second :	9.91
Pivot price	0
Supports	First :	8.44	Second :	8.4
MAs	MA(5) :	0	MA(20) :	0
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	0	D(3) :	0
RSI	RSI(14): 0
52-week	High :	8.48	Low :	8.4

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NBO ] has closed Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Thu, 21 Mar 2024
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors - PR Newswire

Mon, 04 Mar 2024
Northwest Biotherapeutics, Inc (NASDAQ:NWBO) Hits The OTC, What's Next? - Insider Financial

Tue, 06 Feb 2024
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units ... - PR Newswire

Fri, 22 Dec 2023
Northwest Biotherapeutics submits marketing application to UK MHRA for DCVax-L - Seeking Alpha

Thu, 21 Dec 2023
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK ... - PR Newswire

Wed, 22 Nov 2023
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: PNK
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.